- Conditions
- CAR T Cell, CART19, Cell Therapy, Lupus, Lupus Nephritis (LN), SLE, Systemic Lupus Erythematosus (SLE)
- Interventions
- CART19
- Biological
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 10 Years to 29 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 4,571
matching trials from the local directory fallback.
- Conditions
- Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
- Interventions
- SMS001
- Drug
- Lead sponsor
- ToLymph Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hypertension, Obesity
- Interventions
- Angiotensin-(1-7), Saline
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Fabry Disease
- Interventions
- AMT-191
- Drug
- Lead sponsor
- UniQure Biopharma B.V.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 7 more
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
- Interventions
- Abemaciclib, Anastrozole, Biospecimen Collection, Computed Tomography, Diagnostic Imaging Testing, Exemestane, Fludeoxyglucose F-18, Fluorine F 18 Fluoro Furanyl Norprogesterone, Fulvestrant, Gonadotropin-releasing Hormone Analog, Letrozole, Positron Emission Tomography, Tamoxifen, Therapeutic Estradiol
- Drug · Procedure · Other + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Chapel Hill, North Carolina • Seattle, Washington
- Conditions
- Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Diffuse Astrocytoma, IDH-Mutant, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Glioblastoma, IDH-wildtype, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Colorectal Cancer, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Colorectal Cancer, Mismatch Repair Deficient Solid Malignant Tumor, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
- Interventions
- Bevacizumab, Carboplatin, FOLFIRI Protocol, Ipilimumab, NEO212 Oral Capsule, Nivolumab, Paclitaxel, Pembrolizumab, Regorafenib
- Drug
- Lead sponsor
- Neonc Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more
- Conditions
- Asthma
- Interventions
- Whole lung antigen challenge (WLAC), [18F]FEPPA
- Biological · Radiation
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Healthy Volunteer, Smoking E-cigarette, Smoking, Cigarette
- Interventions
- [18F]NOS
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Placebo, TSND-201
- Drug
- Lead sponsor
- Transcend Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Bradenton, Florida
- Conditions
- HCC
- Interventions
- Electroporation Device, GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, INO-9012
- Device · Biological
- Lead sponsor
- Geneos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more
- Conditions
- HIV -1 Infection
- Interventions
- GS-0415, GS-0415 Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Miami Lakes, Florida + 12 more
- Conditions
- Ocular Hypertension (OH), Primary Open Angle Glaucoma (POAG)
- Interventions
- Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®)
- Drug
- Lead sponsor
- YS Life Science Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 14
- States / cities
- Beverly Hills, California • Inglewood, California • Newport Beach, California + 9 more
- Conditions
- Healthy Subjects, Subjective Cognitive Decline (SCD)
- Interventions
- Control - 1Hz Visual Occlusion, Experimental -- 16.67 Hz Visual Occlusion
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 65 Years to 89 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- INS1202
- Genetic
- Lead sponsor
- Insmed Gene Therapy LLC
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- La Jolla, California • Palo Alto, California • Baltimore, Maryland + 4 more
- Conditions
- Geographic Atrophy
- Interventions
- BRX011, Placebo
- Drug
- Lead sponsor
- Biojiva LLC
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 11
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Hattiesburg, Mississippi + 8 more
- Conditions
- Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium, Laparoscopic Radical Prostatectomy with Robotics, Pelvic Lymphadenectomy, Positron Emission Tomography, Relugolix
- Procedure · Other · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Specific Advanced Solid Tumors
- Interventions
- ACR-2316
- Drug
- Lead sponsor
- Acrivon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Newport Beach, California + 12 more
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy
- Interventions
- Surgical implantation of the CPCB-RPE1 implant
- Device
- Lead sponsor
- Regenerative Patch Technologies, LLC
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2040
- U.S. locations
- 5
- States / cities
- Huntington Beach, California • Los Angeles, California • Lemont, Illinois + 2 more
- Conditions
- HPV-Related Carcinoma, Oropharyngeal Cancer
- Interventions
- combined HPV 16 DNA and host gene methylation oral biomarker panel
- Diagnostic Test
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Omaha, Nebraska • Pittsburgh, Pennsylvania
- Conditions
- Osteoporosis
- Interventions
- Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Infusion
- Drug
- Lead sponsor
- Chrissy Kistler
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Chronic Low-back Pain, Diabetic Neuropathic Pain, Osteoarthritis, Knee
- Interventions
- LY3016859 ISA, LY3526318 ISA, LY3556050 ISA, LY3857210 ISA, LY4065967 ISA, Placebo, Placebo Oral
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 52 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- ASTX727, SNDX-5613, Venetoclax
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- High-Risk Localized Prostate Cancer
- Interventions
- EBRT + 24 mo ADT, EBRT + 6 mo ADT + 177Lu-PSMA-617
- Radiation · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic
- Interventions
- LY3971297, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • St Louis, Missouri • Chapel Hill, North Carolina + 1 more